证券代码：920371 证券简称：欧福蛋业 公告编号：2026-006 苏州欧福蛋业股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、报告期内，预计公司实现营业收入 90,521.98 万元，同比下降 0.13%；归 属于上市公司股东的净利润为 8,607.42 万元，同比增长 88.76%；归属于上市公 司股东的扣除非经常性损益的净利润为 8,477.77 万元，同比增长 91.93%；基本 每股收益为 0.4190 元，与上年同期相比增长 88.74%。盈利增长得益于主营业务 盈利质量较高。 2、报告期末，预计公司总资产为 75,467.03 万元，较期初增长 9.64%，资产 规模稳步提升；归属 ...

江苏新天伦（吴江）律师事务所 法律意见书 江苏新天伦（吴江）律师事务所 关于苏州欧福蛋业股份有限公司 2026 年第一次临时股东会的 法律意见书 二零二六年一月 江苏新天伦（吴江）律师事务所 法律意见书 江苏新天伦（吴江）律师事务所 关于苏州欧福蛋业股份有限公司 2026 年第一次临时股东会的 法律意见书 致：苏州欧福蛋业股份有限公司 引言 江苏新天伦（吴江）律师事务所（以下简称"本所"）接受苏州欧福蛋业股 份有限公司（以下简称"欧福蛋业"或"公司"）委托，指派平佳翱律师、赵莹 莹律师（以下简称"本所律师"）出席欧福蛋业 2026 年第一次临时股东会（以 下简称"本次股东会"），对本次股东会的相关事宜进行见证，并出具法律意见 书。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）等有关法律法规和规范性文件以 及《苏州欧福蛋业股份有限公司章程》（以下简称"《公司章程》"）、《苏州欧福蛋 业股份有限公司股东会议事规则》（以下简称"《股东会议事规则》"）的规定而出 具。 律师声明事项 为出具本法律意见书，本所律师对公司本次股东会所涉及的有关事项 ...

证券代码：920371 证券简称：欧福蛋业 公告编号：2026-005 苏州欧福蛋业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 1 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场投票和网络投票相结合 4.会议召集人：董事会 5.会议主持人：董事长 Henrik Pedersen 6.召开情况合法合规的说明： 本次股东会的召集和召开程序等符合《公司法》等有关法律、法规和《公司 章程》的相关规定。会议的召开经第四届董事会第五次会议决议通过，履行了必 要的审批程序。 （二）会议出席情况 出席和授权出席本次股东会的股东共 8 人，持有表决权的股份总数 149,118,352 股，占公司有表决权股份总数的 72.58%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司董事、高级管理人员出席 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [5][8]. Core Viewpoints - The company is a leader in China's egg product processing industry, with strong B-end customer relationships and significant technological barriers. The C-end market is expected to open up new growth opportunities [5][10]. - The Chinese egg product processing market is projected to exceed 50 billion yuan in 2024, with steady growth in downstream demand [7][33]. - The company has established long-term partnerships with major clients such as Unilever and Yum, driving growth through capacity expansion and innovation [10][57]. Summary by Sections 1. Business Overview - The company focuses on the development, production, and sales of liquid eggs, egg powder, and various egg-based prepared products, being a key player in agricultural industrialization [15][18]. - The company has four production bases in China and has been a pioneer in the egg product processing industry, ensuring product quality and safety [15][18]. 2. Industry Analysis - The Chinese egg product processing market is expected to grow significantly, with a market size surpassing 50 billion yuan in 2024 and a year-on-year growth rate of 7% [33][52]. - The processing rate of eggs in China is currently only 5%-7%, indicating substantial room for growth compared to developed countries [44][52]. 3. Customer Relationships and Innovation - The company has established strong ties with major clients, including Unilever and Yum, and is focused on expanding its capacity and enhancing its R&D capabilities [10][57]. - The company has launched innovative products such as egg white functional drinks, targeting both fitness enthusiasts and specific demographics like the elderly [66][68]. 4. Financial Forecast and Valuation - The company is expected to achieve a net profit of 0.89 billion yuan in 2025, with corresponding P/E ratios of 25.8, 22.9, and 20.5 for 2025-2027 [6][8]. - Revenue from liquid eggs is projected to grow steadily, while egg powder and prepared products are also expected to see recovery and growth [9].

Investment Rating - The investment rating for the company is "Outperform" (Maintain) [2] Core Views - The company is positioned as a high-elasticity player in the egg cycle, with growth driven by international expansion and lysozyme projects [2] - The company anticipates a significant increase in net profit for 2025, projecting a range of 80 million to 92 million yuan, representing a year-on-year growth of 75.44% to 101.75% [2] - The report highlights the successful launch of the Sichuan Oufu processing base, which enhances the company's supply chain capabilities and product gross margins due to declining raw egg prices [3] - The international egg price surge in 2025 presents an opportunity for the company to expand its overseas market presence, with successful exports of its lysozyme project contributing to new profit growth [4] Financial Summary - The company expects revenue to grow from 906 million yuan in 2024 to 1.131 billion yuan in 2025, reflecting a year-on-year increase of 24.8% [6] - The projected net profit for 2025 is 84 million yuan, up from 46 million yuan in 2024, indicating an 84.3% year-on-year growth [6] - Gross margin is expected to improve from 16.6% in 2024 to 18.2% in 2025, while net margin is projected to rise from 5.0% to 7.4% [6][9] - The company's earnings per share (EPS) is forecasted to increase from 0.22 yuan in 2024 to 0.41 yuan in 2025, with a corresponding price-to-earnings (P/E) ratio decreasing from 49.3 to 26.7 [6]

Core Viewpoint - Oufu Egg Industry (920371) announced a profit forecast for 2025, expecting a net profit between 80 million to 92 million yuan, representing a year-on-year growth of 75.44% to 101.75% [2] Company Performance - The company's stock closed at 10.94 yuan, down 1.17% on the announcement day, with a turnover rate of 2.21% and a transaction volume of 46.71 million yuan [2] - Over the past five days, the stock has decreased by 0.64% [2] Market Reaction - Historical data indicates that 61.98% of stocks with a profit forecast increase of over 50% saw their prices rise on the announcement day, with 12 companies hitting the daily limit up [2] - In the five days following the announcement, 64.06% of these stocks experienced price increases [2]

Financial Forecast - The company forecasts a net profit of approximately 8,000 to 9,200 million CNY for 2025, representing an increase of 75.44% to 101.75% compared to the previous year's profit of 4,559.99 million CNY[3]. - The performance forecast is preliminary and has not been audited by an accounting firm, emphasizing the need for investors to exercise caution[5]. Business Expansion - The primary reason for the significant growth in 2025 is the commencement of operations at the largest egg product processing base in Southwest China, Sichuan Oufu, enhancing the company's industrial layout across four major economic regions[3]. - The company is expanding its C-end business with new retail products, including small-packaged egg liquids and welfare-certified eggs, which have gained consumer recognition and achieved substantial growth[4]. - The international market for egg products has seen increased demand, particularly due to rising prices in the U.S., Japan, and South Korea, providing significant opportunities for overseas expansion[4]. - The company's lysozyme project has successfully commenced production and has been exported, creating a new profit growth point by matching customer needs[4]. - The company has completed its industrial layout, achieving coordinated development across its supply chain and significantly controlling logistics costs[4]. Customer Focus - The company has focused on B-end customers, emphasizing food safety and quality, which has strengthened customer loyalty and improved gross profit margins due to a decrease in raw egg prices[4].

Group 1 - The "Healthy China" strategy is driving an increase in residents' health literacy, with a projected level of 31.87% by 2024, up 2.17 percentage points from 2023 [6][10][11] - The silver economy is expected to exceed 9 trillion yuan by 2025, accounting for 6% of GDP, and reach 30 trillion yuan by 2035, indicating significant growth potential [6][11] - The Z generation has integrated health into their fixed living expenses, with 47.0% of young people frequently purchasing health products/services, leading to a high penetration rate of 84.3% in health consumption [19][21][22] Group 2 - The nutritional functional food market in China is projected to reach 233.1 billion yuan in 2024, with an annual compound growth rate (CAGR) of 8.5% expected from 2024 to 2029 [28][38] - The market for special medical foods is expected to grow at a CAGR of 26% from 2019 to 2024, with the market size increasing from 7.3 billion yuan in 2019 to 23.2 billion yuan in 2024 [28][15] - The konjac food market has shown a CAGR of 20% from 2014 to 2023, with consumption trends on the rise, particularly among younger demographics [28][39] Group 3 - The nutritional functional food industry is characterized by a diverse range of subcategories, including weight management, sports nutrition, beauty nutrition, gut health, healthy snacks, and basic nutrition, with sports nutrition being the fastest-growing segment [30][39] - The contract manufacturing market for nutritional functional foods is expected to grow from 25.3 billion yuan in 2024 to 44.1 billion yuan by 2029, with a CAGR of 11.8% [42][38] - The health snack segment is the largest application scenario within the nutritional functional food market, projected to reach 97.1 billion yuan in 2024 [38][41] Group 4 - Companies like Kangbiter, a leading brand in sports nutrition, and Hengmei Health, a contract manufacturer of nutritional functional foods, are positioned to benefit from the growing health consumption trend [28][46][48] - The nutritional functional food industry is experiencing rapid development, with increasing competition among brands and a focus on product innovation to meet diverse consumer demands [30][38] - The overall market for nutritional health foods is expected to reach 522.3 billion yuan in 2024, with a forecasted growth to 720.3 billion yuan by 2029, driven by rising consumer health awareness and regulatory improvements [30][34]

关于苏州欧福蛋业股份有限公司 2026 年日常性关联交易预计的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"保 荐机构"）作为苏州欧福蛋业股份有限公司（以下简称"欧福蛋业"、"公司"） 向不特定合格投资者公开发行股票并在北交所上市的保荐机构，根据《证券发行 上市保荐业务管理办法》《北京证券交易所股票上市规则》《北京证券交易所证 券发行上市保荐业务管理细则》等有关规定，对欧福蛋业 2026 年度日常关联交 易预计的事项进行了审慎核查，核查意见如下： 一、关联交易基本情况 （一）关联交易概述 申万宏源证券承销保荐有限责任公司 为了规范公司的经营行为，保护股东的合法权益，公司结合业务发展情况， 对公司（含子公司）与其关联方的 2026 年度日常关联交易情况进行了预计。本 次关联交易未构成《上市公司重大资产重组管理办法》规定的重大资产重组。 | （二）本次关联交易预计类别和金额 | | --- | 单位：万元 | | 关联交 | 交易内容 | 预计 2026 生不含税交易金 | 年发 | 2025 年与 关联方实际 | 预计金额与上年 实际发生金额差 | | --- | --- | -- ...

关于预计 2026 年日常性关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 （一） 预计情况 单位：元 | 关联交易类别 | 主要交易内容 | 预计 2026 年发生 | 2025 年与关联 | 预计金额与上年实际发生金额差 | | --- | --- | --- | --- | --- | | | | 金额 | 方实际发生金额 | 异较大的原因 | | | 购买原材料 | 51,700,000.00 | 27,748,967.39 | 公司在预计日常关联交易额度时 | | | | | | 是基于市场需求和业务开展进度 | | 购买原材料、 | | | | 的判断，以与关联方可能发生业务 | | 燃料和动力、 | | | | 的上限金额进行预计的，实际发生 | | 接受劳务 | | | | 总金额与预计总金额存在一定差 | | | | | | 异，属于正常经营行为，对公司日 | | | 出售商品 | 60,000,000.00 | 9,640,926.62 | ...